Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 50
- 主要终点
- Incidence of thyroid disfunction
研究概览
简要总结
Recently, the occurrence and potential impact of pituitary dysfunction after aSAH has gained increasing interest. Several studies have demonstrated pituitary dysfunction after SAH suggesting that pituitary dysfunction may be a contributing factor for residual symptoms after SAH. This is an observational multicentric study aimed to test the prevalence of thyroid abnormalities, other neuroendocrinological dysfunction and their influence on outcome of patients affected by aSAH.
详细描述
The incidence of aneurysmal subarachnoid hemorrhage (aSAH) varies between 6 to 10/100,000 subjects per year and it is a major cause of death and disability. The mortality rate ranges from 40 to 50%, and those who do survive SAH have high rates of functional limitations that could lead to impaired quality of life, including fatigue, depression, and loss of motivation.
Because aSAH affects patients in their most productive years of life, the disease has important social, and economic implications, and early prediction of long-term outcome is based on multiple factors including the primary injury secondary insults as well as neurorehabilitation interventions.
Recently, the occurrence and potential impact of pituitary dysfunction after aSAH has gained increasing interest. Several studies have demonstrated pituitary dysfunction after SAH suggesting that pituitary dysfunction may be a contributing factor for residual symptoms after SAH. However, questions remain about the real prevalence and impact of such dysfunction on patients' outcome both in the acute and chronic phase after these events.
In two recent metanalysis, the prevalence of total pituitary dysfunction was found with pooled frequencies of 0.31 (95% confidence interval CI: 0.22-0.43) [Can et a.] and 49.3.0% (95% CI 41.6%-56.9%) [Robba et al] during the acute phase (< 6 months from aSAH) and decreasing in the chronic phase to 0.25 (95% CI: 0.16-0.36) [Can et al.] and 25.6% (95% CI 18.0%-35.1%) [Robba et al]. However, the authors found high heterogenicity and different results between the available literature; many differences were found in the in the choice of time of pituitary function assessment and SAH, of diagnostic criteria and units of measurement used to establish the diagnosis of hypopituitarism after SAH.
Finally, it is not clear which is the hormone axis more likely to be affected after aSAH.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with acute aneurysmal SAH aged between 18 and 70 years of age who could be subjected to endocrine evaluation within 10 days of ictus and at follow-up.
排除标准
- •be major depression, psychiatric premorbidity, pituitary adenoma or perisellar lesion,preexisting hypopituitarism of any degree, previous hormonal substitution, patients in moribund state, pregnancy, glucocorticoid medication on admission to hospital or during treatment, prior pituitary insufficiency, and unsalvageable aSAH.
结局指标
主要结局
Incidence of thyroid disfunction
时间窗: 12 months after aSAH
Thyroid-stimulating hormone (TSH), free thyroxin (fT4), free triiodothyronine (fT3).
次要结局
- Incidence of pituitary- sexual hormones disfunction(At 2 weeks, and at follow up at 3, 6 and 12 months.)
- Survival(At 2 weeks, and at follow up at 3, 6 and 12 months)
- Incidence of pituitary-adrenal axis disfunction(At 2 weeks, and at follow up at 3, 6 and 12 months.)
- Incidence of growth hormone insufficiency(At 2 weeks, and at follow up at 3, 6 and 12 months)
- Incidence of language disorders(At 2 weeks, and at follow up at 3, 6 and 12 months)
- Incidence of memory disorders(At 2 weeks, and at follow up at 3, 6 and 12 months)
- Incidence of attention disorders(At 2 weeks, and at follow up at 3, 6 and 12 months)
研究者
Dr. Rita Bertuetti
Medical Doctor
Cambridge University Hospitals NHS Foundation Trust